Qinglei Li, an assistant professor in Texas A&M's College of Veterinary Medicine & Biomedical Sciences, is part of a team of researchers led by Martin Matzuk at Baylor College of Medicine and James Bradner at Dana-Farber Cancer Institute who made the discovery, and their work is published in the journal Cell.
Working on mice, the team found that a compound called JQ1 acts as an inhibitor to sperm production and also sperm mobility.
"Both of these are needed for fertility, but JQ1 prevents both," Li says of the findings.
"It stopped the sperm production very dramatically. More good news is that there appear to be no side effects whatsoever. Once the JQ1 was no longer given to the mice, they were back to their normal reproduction rates, and it did not affect mating behavior or the health of the offspring."
Though the mice were given injections, the team believes that a pill could eventually be developed for the same results.
A male contraceptive pill has been talked about for decades, but so far none has been successfully created despite a strong demand.
While many men might be reluctant to take out the trash or ask for directions if they are lost, recent studies have shown that about 70 percent of men would be willing to take a birth control pill if it were available.
One drawback to many female contraceptives is that they sometimes interfere with hormones, especially estrogen. But Li says the team is confident that JQ1 does not affect testosterone levels in men, and appears to have no other side effects as well.
As with many discoveries, the JQ1 compound appears to have come about by accident.
It was originally used for anti-cancer treatments, but researchers found it was also an excellent compound in controlling fertility.
"This is an exciting step in male contraception," Li adds.
"A compound with more specificity will be needed before clinical trials can be done for humans. It does not mean a male birth control just yet, but it is a great step forward in that direction."
About Research at Texas A&M University
As one of the world's leading research institutions, Texas A&M is in the vanguard in making significant contributions to the storehouse of knowledge, including that of science and technology. Research conducted at Texas A&M represents an annual investment of more than $700 million. That research creates new knowledge that provides basic, fundamental and applied contributions resulting in many cases in economic benefits to the state, nation and world.
Advertise with us - Download World Pharma News' Media Pack Read more
August marks National Psoriasis Awareness Month, an opportunity to raise awareness about psoriasis, a skin disease that affects nearly 7.5 million Americans. For those living with this condition, finding information Read more
AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialisation of prescription medicines. As a leader in gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, Read more
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in Read more
Novartis provides healthcare solutions that address the evolving needs of patients and societies. Focused solely on healthcare, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving Read more
GlaxoSmithKline - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better Read more
Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: Read more
The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 142 affiliates in 50 countries and more than 41,500 Read more
Headquartered in Denmark, Novo Nordisk is a global healthcare company with 87 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth Read more